University of California, San Francisco Cutaneous Oncology and Melanoma Center — San Francisco, California

University of California, San Francisco Cutaneous Oncology and Melanoma Center is a clinical research site located in San Francisco, California, United States 9411.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

University of California, San Francisco Cutaneous Oncology and Melanoma Center has participated in 1 clinical trials.

Therapeutic areas: Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site.

Sponsors: Celgene.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of California, San Francisco Cutaneous Oncology and Melanoma Center?

University of California, San Francisco Cutaneous Oncology and Melanoma Center has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of California, San Francisco Cutaneous Oncology and Melanoma Center conducted?

University of California, San Francisco Cutaneous Oncology and Melanoma Center has 1 clinical trials on record. Their work covers Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site.

Is University of California, San Francisco Cutaneous Oncology and Melanoma Center accredited by Crixeo Health?

University of California, San Francisco Cutaneous Oncology and Melanoma Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of California, San Francisco Cutaneous Oncology and Melanoma Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.